The story appears on

Page A3

July 14, 2020

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Metro

Clinical trials completed

PHASE 1 clinical trials on a homegrown neutralizing antibody treatment for the novel coronavirus have been completed in Shanghai.

The new drug, JS016, was given to 40 healthy volunteers. The trials are the first of its kind to test neutralizing antibody treatment against the coronavirus in healthy people.

The trials showed the drug was safe and tolerable for human use.

JS016 is co-developed by Shanghai Junshi Biosciences and the Institute of Microbiology under the Chinese Academy of Sciences.

Clinical trials began at the Huashan Hospital on June 7, and led by Dr Zhang Jing and Dr Zhang Wenhong, who is also the leader of the expert team for coronavirus treatment in Shanghai.

The 40 volunteers were given the drug by July 7. To date, no side effects related to the doses have not been found.

Junshi said the company plans to start clinical trials on affected people as soon as possible.

Previous tests on monkeys showed JS016 can block the virus from entering cells, and decrease the virus in the lungs of affected monkeys.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend